Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

23/24/23	Bausch + Lomb Corporation acquired TearLab Corporation from Accelmed Partners and other shareholders for approximately $24 million.	CI
09/21/09	TearLab Corporation Announces Board Appointments	CI
09/21/09	TearLab Corporation Appoints Adam Szaronos as Chief Executive Officer	CI
09/21/09	Tearlab Corporation Appoints James V. Mazzo to the Company's Board of Directors	CI
16/21/16	MellingMedical and TearLab Agreement Aims to Enhance Early Detection of Dry Eye Disease in American Veterans	CI
29/20/29	TearLab Appoints Adam Szaronos as Chief Commercial Officer	CI
09/20/09	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) completed the acquisition of TearLab Corporation.	CI
09/20/09	TearLab Corporation to Seek Acquisitions	CI
26/20/26	Tearlab Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	CI
11/20/11	TearLab Corporation Announces Board Appointments	CI
11/20/11	Tearlab Mulls Inorganic Growth Opportunities	CI
11/20/11	TearLab Corporation announced that it expects to receive $25 million in funding from Accelmed Fund	CI
11/20/11	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) entered into term sheet to acquire TearLab Corporation for $0.74 million.	CI

09/20/09	TEARLAB CORP : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
27/20/27	TearLab: 1Q Earnings Snapshot	AQ
26/20/26	TEARLAB : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
09/20/09	TEARLAB : Entry into a Material Definitive Agreement (form 8-K/A)	AQ
30/20/30	TEARLAB CORP : Entry into a Material Definitive Agreement (form 8-K)	AQ

Manager	Title	Age	Since
Adam Szaronos CEO	Chief Executive Officer	-	01/04/2026
Benjamin Sullivan CTO	Chief Tech/Sci/R&D Officer	-	17/07/2009
John Lund DFI	Director of Finance/CFO	60	01/07/2022

Director	Title	Age	Since
Uri Geiger BRD	Director/Board Member	58	09/07/2020
James V. Mazzo CHM	Chairman	68	09/12/2021
Richard Lindstrom BRD	Director/Board Member	78	01/09/2004

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
09/07/20	Joseph S. Jensen	Tender	Chief Executive Officer	29,206	0.1196%
09/07/20	Michael Marquez	Tender	Chief Financial Officer	500	0.0020%	-
09/07/20	Paul M. Karpecki	Tender	Director	1,02,200	0.4187%

TearLab Corporation Share Price

Stocks

Medical Equipment, Supplies & Distribution

Latest news: TearLab Corporation

Press Releases: TearLab Corporation

Managers and Directors: TearLab Corporation

Latest insider transactions

Glasses, Spectacles & Contact Lenses

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TEARLAB CORPORATION	-.--%	+2.84%	-	-	14.13L
ABBOTT LABORATORIES	-1.58%	-2.36%	-26.30%	+1.74%	17TCr
MEDTRONIC PLC	-1.34%	-0.19%	-11.69%	+14.19%	11TCr
STRYKER CORPORATION	-1.84%	+0.43%	-23.57%	+5.31%	11TCr
ESSILORLUXOTTICA	+1.52%	+1.45%	-46.87%	-10.58%	7.44TCr
CENCORA, INC.	-0.24%	+2.09%	+2.85%	+70.80%	6.01TCr
HOYA CORPORATION	+3.27%	+7.25%	+18.14%	+67.16%	5.19TCr
BECTON, DICKINSON AND COMPANY	+0.45%	-0.42%	-5.62%	-30.95%	4.92TCr
IDEXX LABORATORIES, INC.	-1.94%	-2.90%	-17.50%	+16.14%	4.15TCr
DEXCOM, INC.	-3.69%	-3.58%	+25.88%	+0.38%	3.28TCr
Average	-0.54%	+0.62%	-9.41%	+14.91%	7.83TCr
Weighted average by Cap.	-0.77%	+0.42%	-15.57%	+12.18%